Literature DB >> 10508256

Mapping the site on human IgG for binding of the MHC class I-related receptor, FcRn.

J K Kim1, M Firan, C G Radu, C H Kim, V Ghetie, E S Ward.   

Abstract

The analysis of the pharmacokinetics of wild-type and mutated Fc fragments derived from human IgG1 indicates that Ile253, His310 and His435 play a central role in regulating serum half-life in mice. Reduced serum half-life of the recombinant, mutated fragments correlates with decreased binding to the MHC class I-related neonatal Fc receptor, FcRn. In addition, the analysis of an Fc fragment in which His435 is mutated to Arg435 demonstrates that the sequence difference at this position between human IgG1 (His435) and IgG3 (Arg435) most likely accounts for the shorter serum half-life of IgG3 relative to IgG1. In contrast to His310 and His435, the data indicate that His433 does not play a role in regulating the serum half-life of human IgG1. Thus, the interaction site of mouse FcRn on human and mouse IgG1 involves the same conserved amino acids located at the CH2-CH3 domain interface of the IgG molecule. The sequence similarities between mouse and human FcRn suggest that these studies have direct relevance to understanding the factors that govern the pharmacokinetics of therapeutic IgG.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10508256     DOI: 10.1002/(SICI)1521-4141(199909)29:09<2819::AID-IMMU2819>3.0.CO;2-6

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  80 in total

Review 1.  Transcytosis and catabolism of antibody.

Authors:  Victor Ghetie; E Sally Ward
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

2.  pH-dependent binding engineering reveals an FcRn affinity threshold that governs IgG recycling.

Authors:  M Jack Borrok; Yanli Wu; Nurten Beyaz; Xiang-Qing Yu; Vaheh Oganesyan; William F Dall'Acqua; Ping Tsui
Journal:  J Biol Chem       Date:  2014-12-23       Impact factor: 5.157

3.  Divergent activities of an engineered antibody in murine and human systems have implications for therapeutic antibodies.

Authors:  Carlos Vaccaro; Roger Bawdon; Sylvia Wanjie; Raimund J Ober; E Sally Ward
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-20       Impact factor: 11.205

4.  Tailoring the pharmacokinetics and positron emission tomography imaging properties of anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments.

Authors:  Vania Kenanova; Tove Olafsen; Desiree M Crow; Gobalakrishnan Sundaresan; Murugesan Subbarayan; Nora H Carter; David N Ikle; Paul J Yazaki; Arion F Chatziioannou; Sanjiv S Gambhir; Lawrence E Williams; John E Shively; David Colcher; Andrew A Raubitschek; Anna M Wu
Journal:  Cancer Res       Date:  2005-01-15       Impact factor: 12.701

5.  Improved tumor imaging and therapy via i.v. IgG-mediated time-sequential modulation of neonatal Fc receptor.

Authors:  Jaspreet Singh Jaggi; Jorge A Carrasquillo; Surya V Seshan; Pat Zanzonico; Erik Henke; Andrew Nagel; Jazmin Schwartz; Brad Beattie; Barry J Kappel; Debjit Chattopadhyay; Jing Xiao; George Sgouros; Steven M Larson; David A Scheinberg
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808

Review 6.  Targeting FcRn for the modulation of antibody dynamics.

Authors:  E Sally Ward; Siva Charan Devanaboyina; Raimund J Ober
Journal:  Mol Immunol       Date:  2015-03-09       Impact factor: 4.407

7.  Distribution of the IgG Fc receptor, FcRn, in the human fetal intestine.

Authors:  Uzma Shah; Bonny L Dickinson; Richard S Blumberg; Neil E Simister; Wayne I Lencer; W Allan Walker
Journal:  Pediatr Res       Date:  2003-02       Impact factor: 3.756

8.  Cross-species binding analyses of mouse and human neonatal Fc receptor show dramatic differences in immunoglobulin G and albumin binding.

Authors:  Jan Terje Andersen; Muluneh Bekele Daba; Gøril Berntzen; Terje E Michaelsen; Inger Sandlie
Journal:  J Biol Chem       Date:  2009-12-14       Impact factor: 5.157

Review 9.  Targeting FcRn to Generate Antibody-Based Therapeutics.

Authors:  E Sally Ward; Raimund J Ober
Journal:  Trends Pharmacol Sci       Date:  2018-08-22       Impact factor: 14.819

10.  Structural insights into neonatal Fc receptor-based recycling mechanisms.

Authors:  Vaheh Oganesyan; Melissa M Damschroder; Kimberly E Cook; Qing Li; Changshou Gao; Herren Wu; William F Dall'Acqua
Journal:  J Biol Chem       Date:  2014-01-27       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.